Neogenomics Inc(NEO) Price Forecast & Company Analysis. P/E · Dividend · Earnings · Price Target · RSI · MACD | US Stocks Today
Oct 27 at 4:47 PM ET (Korea 10/28 05:47)
Full metrics table
| Index | RUT | P/E | - | EPS (ttm) | -0.4 | Insider Own | 1.93% | Shs Outstand | 127.9M | Perf Week | 3.91% |
| Market Cap | 2.22B | Forward P/E | 50.39 | EPS next Y | 83.01% | Insider Trans | -1.22% | Shs Float | 126.0M | Perf Month | -10.47% |
| Enterprise Value | 2.52B | PEG | 0.9 | EPS next Q | 0.06 | Inst Own | 113.8% | Short Float | 11.28% | Perf Quarter | 13.1% |
| Income | -0.05B | P/S | 2.9 | EPS this Y | 56.06% | Inst Trans | 10.47% | Short Ratio | 6.58 | Perf Half Y | 91.46% |
| Sales | 0.77B | P/B | 2.81 | EPS next 5Y | 55.85% | ROA | -3.78% | Short Interest | 14.22M | Perf YTD | 46.85% |
| Book/sh | 6.14 | P/C | 15.25 | EPS past 3/5Y | 10.12% - | ROE | -6.33% | 52W High | -14.29% ($20.15) | Perf Year | 69.98% |
| Cash/sh | 1.13 | P/FCF | - | Sales past 3/5Y | 12.58% 10.35% | ROIC | -4.22% | 52W Low | 144.44% ($7.07) | Perf 3Y | 26.89% |
| Dividend Est. | - | EV/EBITDA | 217.01 | EPS Y/Y TTM | 50.58% | Gross Margin | 41.74% | Volatility(W/M) | 4.2% 5.42% | Perf 5Y | -61.15% |
| Dividend TTM | - | EV/Sales | 3.29 | Sales Y/Y TTM | 11.19% | Oper. Margin | -7.03% | ATR (14) | 0.84 | Perf 10Y | 111.38% |
| Dividend Ex-Date | - | Quick Ratio | 3.34 | EPS Q/Q | 104.85% | Profit Margin | -6.77% | RSI (14) | 51.06 | Recom | 1.5 |
| Dividend Gr. 3/5Y | - | Current Ratio | 3.6 | Sales Q/Q | 11.21% | SMA20 | 1.81% ($16.96) | Beta | 1.87 | Target Price | $21.95 |
| Payout | - | Debt/Eq | 0.57 | Earnings | 2026/10/28 | SMA50 | -1.87% ($17.6) | Rel Volume | 1.27 | Prev Close | $16.69 |
| Employees | 2500 | LT Debt/Eq | 0.56 | EPS/Sales Surpr. | 49.25% 2.4% | SMA200 | 35.89% ($12.71) | Avg Volume(3M) | 2.16M | Price | $17.27 |
| IPO | 1999/11/10 | Option/Short | Yes/Yes | Trades | 13825 | Volume | 2,751,392 | Change | 3.48% |
🔬 NeoGenomics (NEO) is a specialty clinical laboratory company focused on cancer diagnostics. It operates a cancer genetics and molecular diagnostic testing network in the United States and the United Kingdom, offering physicians, hospitals, and pharmaceutical companies a broad test menu spanning solid tumors, hematologic malignancies, and hereditary cancers. With a two-pronged focus on clinical testing and advanced diagnostics, the company is strengthening its position in the precision oncology market.
Over the past 1 year, on the higher side
14% below its 1-year high.
Traded more than usual. That is 127% of its average volume.
Next earnings report: October 28
1 days to go.
NEO has a sound balance sheet but weak earning power
Of every $100 in sales, $7.03 is lost.
Tap to view numbers
Earnings are growing steadily
Earnings are expected to grow by +56.1% this year.
Tap to view numbers
Relative to sales, the price is about the industry average
Loss-making, so we compare on sales. For a company selling $100 a year, you would pay $290. Peers typically go for $441.
Tap to view numbers
Results came in about as expected
Slight tendency to beat estimates
Tap to view numbers
The outlook is positive
Analyst sentiment is Strong Buy.
Tap to view numbers
Holding long would have lost money
Bought 5 years ago, your return today would be -61.1%. The S&P 500 did +70% over the same period.
Tap to view numbers
No dividend
There is no profit to distribute yet.
Ownership is about average
Institutions hold 113.8%.
Tap to view numbers
Multiple ETFs hold this stock
Buying this ETF gives you exposure to this stock as well.
It ranks #25 of 44 in the industry
Based on market cap of $2B.
CDNA#24 Caredx Inc $4B PER 34.0 NEO#25 Neogenomics Inc $2B PER - 
WGS#26 GeneDx Holdings Corp $2B PER - 
PSNL#27 Personalis Inc $2B PER - 
FRNM#28 Freenome Inc $1B PER - 
FAQ
What kind of company is NEO?
NEO belongs to the Healthcare sector and operates in the Diagnostics & Research industry.
What is the market cap of NEO?
The market cap of NEO is approximately $2.2B, ranking 1,974 within its sector.
What is the 52-week high and low for NEO?
NEO has recorded a 52-week high of $20.15 and a low of $7.07.
